Headquartered in Building Two, Galway Fiscal year ends April NYSE: MDT medtronic.com
Medtronic plc is a global healthcare technology company that develops and manufactures medical devices and therapies across cardiovascular, neuroscience, medical surgical, and diabetes care. The company's portfolio spans cardiac devices (including pacemakers, defibrillators, cardiac ablation systems, and structural heart solutions), cranial and spinal surgical technologies, surgical robotics, neuromodulation therapies, patient monitoring systems, insulin pumps, and continuous glucose monitors. Medtronic serves healthcare systems in more than 150 countries with approximately 95,000 employees. The company is in the process of separating its Diabetes business through potential capital markets transactions, which may include a spin-off, split-off, or offering. In fiscal 2027, the Cardiovascular Portfolio was reorganized into Electrophysiology Therapies, Interventional Cardiology Therapies, CardioVascular Surgery, and Peripheral Vascular Health divisions. The company trades on the NYSE under the ticker MDT. Updated
Medtronic's CEO just took $4.75 million off the table, trimming 18% of his personal stake right after the company raised fiscal 2027 guidance. No 10b5-1 plan was disclosed on the filing, which makes it a discretionary sale.
Cramer's point for anyone holding bank stocks: solid results are no longer being rewarded, and the charts have turned ugly regardless. The bigger swing factor is oil. If the war ends, he expects crude to be cut in half, which would reset inflation and the Fed debate overnight.
Cramer wants to add software as the bounce-back trade and the beaten-down industrial names tied to data center power. He also warns that rising rates are the real threat heading into earnings season in a couple of weeks.
Medtronic raised its FY27 organic revenue growth outlook to 7.25% to 7.75% after beating on both lines, and that guidance lift matters more than a fifth straight EPS beat. Cardiovascular carried it, led by Electrophysiology Therapies revenue up 29.5%.
Seventy-nine companies report next week, and Tuesday morning does the heavy lifting: NIO and Medtronic both deliver before the open, one a read on Chinese EV demand, the other on medtech spending. Monday starts quieter with SAIC and a run of small-cap international names.
A dividend that keeps growing beats a fat yield that gets cut, but only if the company can actually afford to keep raising it. These five blue chips clear that bar, and…
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics. Three healthcare stocks prove that the most reliable paycheck…
Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than…
A 26% price drop on a stock with a near-monopoly business model and 85% recurring revenue sounds like a warning, but one investor sees it as an invitation to keep buying.
Both Medtronic and Abbott have dropped in 2026, and those declines reshuffled the math on yield, valuation, and long-term growth in ways that push retirement investors toward a clear but maybe surprising…
One of these stocks lost nearly a fifth of its value over the past year, another nearly doubled, and both still handed shareholders a bigger check. Find out whether the dividends behind…
Medtronic has raised its dividend for 49 straight years while the stock quietly lost a fifth of its value, but something in the operating room just changed the entire conversation about why…
Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One…
A bond coupon that felt safe a decade ago may be quietly bleeding your retirement dry, and Dave Ramsey's hurdle-rate math explains exactly why. The question is which assets can actually climb…
Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons…
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made…
Intuitive Surgical is down more than 30% this year, and one investor keeps buying anyway, convinced that a once-per-decade hardware cycle and an $8.6 billion cash fortress make the drawdown a gift…
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where…
Intuitive Surgical has shed a third of its value while its robotic surgery peers barely flinched, and Wall Street's most bullish analyst sees an outcome that would leave anyone who sold near…
Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the…
Medtronic plc is a global healthcare technology company that develops and manufactures medical devices and therapies across cardiovascular, neuroscience, medical surgical, and diabetes care.
24/7 Wall St.'s 12-month price target for MDT is $114.58, rated Buy. The Wall Street consensus target is $104.62. MDT price prediction →
